MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
GBS Operating Income 2011-2026 | GBS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income GBS
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.6 M | -10.3 M | -12.6 M | -8.34 M | -5.57 M | -2.86 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.86 M | -12.6 M | -8.38 M |
Quarterly Operating Income GBS
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.64 M | -3 M | - | -2.55 M | -2.26 M | -2.73 M | - | -2.95 M | -1.99 M | -2.53 M | - | -6.54 M | -2.13 M | - | -3.35 M | -1.34 M | -3.47 M | -1.44 M | -4.91 M | -3.14 M | -917 K | -663 K | -917 K | -28.8 K | -1.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -28.8 K | -6.54 M | -2.44 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alphatec Holdings
ATEC
|
-82.1 M | $ 11.29 | 3.58 % | $ 1.69 B |  USA |
 |
AxoGen
AXGN
|
-7.85 M | $ 33.05 | 3.41 % | $ 1.52 B | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Align Technology
ALGN
|
608 M | $ 179.93 | 3.92 % | $ 13.5 B | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 12.43 | 2.14 % | $ 1.68 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-14.7 M | $ 0.6 | -2.07 % | $ 37.3 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Bio-Rad Laboratories
BIO
|
269 M | $ 287.63 | 3.05 % | $ 8.12 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.38 | 2.42 % | $ 127 M |  France |
 |
BioSig Technologies
BSGM
|
-71.1 M | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 38.99 | 3.74 % | $ 5.81 K | USA |
 |
Boston Scientific Corporation
BSX
|
3.61 B | $ 63.02 | 2.04 % | $ 93.3 B | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 9.88 | 13.77 % | $ 280 M | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.97 | 4.23 % | $ 1.2 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
IRIDEX Corporation
IRIX
|
-2.57 M | $ 1.02 | 2.01 % | $ 17.3 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 24.7 | 2.4 % | $ 209 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Inogen
INGN
|
-30.2 M | $ 6.44 | 1.74 % | $ 171 M | USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
LivaNova PLC
LIVN
|
199 M | $ 64.47 | 2.69 % | $ 3.52 B |  Britain |
 |
LENSAR
LNSR
|
-24.6 M | $ 5.9 | 3.55 % | $ 70.6 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 16.92 | 5.95 % | $ 397 M | USA |
 |
Globus Medical
GMED
|
480 M | $ 92.74 | 2.62 % | $ 12.5 B | USA |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 4.28 | 4.27 % | $ 906 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
660 K | $ 10.45 | 4.03 % | $ 374 M | USA |
 |
Myomo
MYO
|
-14.4 M | $ 0.72 | 4.35 % | $ 30.1 M | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 54.65 | 1.2 % | $ 1.61 B | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 38.52 | 4.83 % | $ 1.2 B | USA |
 |
NanoVibronix
NAOV
|
-3.58 M | - | - | $ 1.08 M | USA |
 |
Integer Holdings Corporation
ITGR
|
221 M | $ 87.51 | 2.78 % | $ 3.04 B | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.67 | -0.05 % | $ 122 M | USA |